In a turbulent market environment, Precigen Inc. (NASDAQ:PGEN) stock has tumbled to a 52-week low, reaching a price level of just $0.77. According to InvestingPro data, the company maintains a positive aspect with more cash than debt on its balance sheet, though analysts anticipate sales decline in the current year. This significant downturn reflects a challenging period for the biotechnology company, which has seen its stock value erode by 34% over the past year. Investors have been cautious as the company navigates through a landscape marked by regulatory hurdles and competitive pressures, contributing to the stock's underperformance relative to the broader market. The 52-week low serves as a stark indicator of the hurdles Precigen faces as it strives to regain its footing and investor confidence in the coming months. InvestingPro analysis suggests the stock is currently undervalued, with 10+ additional ProTips available to subscribers, including detailed insights on the company's financial health and growth prospects.
In other recent news, Precigen Inc. has regained all previously licensed rights from Alaunos Therapeutics, Inc. after terminating a material definitive agreement. This termination nullifies an Amended and Restated License Agreement that granted Alaunos certain licenses to utilize Precigen’s technology. Precigen has also made significant progress with its PRGN-2012 gene therapy program for recurrent respiratory papillomatosis, with clinical trial results showing a significant reduction in surgeries for over half of the patients.
The company plans to submit a Biologics License Application by the end of 2024, targeting potential commercialization for 2025. In a strategic move, Precigen has implemented workforce reduction and cost-saving measures, raising $31.4 million through an equity issuance. Additionally, Precigen has granted performance stock units to key executives, contingent upon meeting specific operational milestones related to PRGN-2012.
Meanwhile, Jeffrey Perez, Senior Vice President of Intellectual Property Affairs, is set to leave Precigen effective November 1, 2024. H.C. Wainwright, an independent analyst firm, maintains a Buy rating for Precigen, projecting PRGN-2012 to generate risk-adjusted revenue of $106 million in 2026, growing to $521 million by 2030. These recent developments underscore Precigen's commitment to advancing its gene therapy program and maintaining financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.